Satellite symposia are non-commercial, grant- funded learning activities that are planned and conducted by the corporate community in conjunction with AMCP 2025. Satellite symposia offer continuing pharmacy education (CPE) credit, and some offer continuing medical education (CME) credit and continuing nursing education (CNE) credit.
Registration, content, and continuing education are the sole responsibility of the provider. There is no fee for pre-registering for these educational activities, as registration is for planning purposes only.
Satellite program information will be available in late January.
For more information, please contact us.
- Monday, March 31, 2025 | 6:00 pm - 8:00 pm
-
Location:340
PayerTalkCE® Presents: Managed Care Strategies to Improve Outcomes for Macular Telangiectasia
Provider: Impact Education, LLC and Partners in Advancing Clinical Education
Supported by: neurotech
Contact hours: 1.5 CPE/CME/CNE creditsProgram Description
With agents in late-stage development for the treatment of MacTel, managed care professionals must remain informed regarding available clinical trial data and prepare to incorporate emerging treatments into coverage policies to optimize healthcare resources and improve patient outcomes. Managed care pharmacists and other payer professionals will receive knowledge on the timely diagnosis and appropriate treatment of MacTel, including the current and evolving clinical data, the need for multidisciplinary patient care, and benefit design strategies to ensure access to appropriate and effective MacTel therapy.
Learning Objectives
- Describe the natural history, disease mechanisms, and clinical goals of timely treatment of macular telangiectasia
- Review the safety and efficacy data for current and emerging macular telangiectasia treatment options
- Describe the value of multidisciplinary care approaches for patients with macular telangiectasia to improve patient outcomes and coordination of care
- Identify benefit design strategies that ensure access to appropriate and effective macular telangiectasia therapies
Program Manager
Allison Hartless
Impact Education, LLC
allison.hartless@impactedu.net
- Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 340
Managed Care Review Board™ Presents: Health Plan Best Practice Insights to Improve Outcomes for Non-Small Cell Lung Cancer
Provider: Impact Education, LLC and Medical Education Resources, Inc.
Supported by: Regeneron Pharmaceuticals, Inc.
Contact hours: 1.5 CPE/CME/CNE creditsProgram Description
Attendees will learn about current treatment paradigms, emerging treatment options, and current screening and biomarker testing guidelines for NSCLC. This symposium will also address how to evaluate the cost-effectiveness of various NSCLC treatment options to inform decision-making and optimize health care resource allocation, all while touching on the impact of social determinants of health on patients with NSCLC.
Learning Objectives
- Outline current recommendations for screening of NSCLC and characterization of the disease at diagnosis to drive appropriate treatment selection
- Evaluate the cost-effectiveness of various treatment options for NSCLC to inform decision-making and optimize healthcare resource allocation
- Discuss relevant social determinants of health-related to NSCLC treatment
Program Manager
Allison Hartless
Impact Education, LLC
allison.hartless@impactedu.net - Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 330
Managed Care Considerations for Managing Myelofibrosis With JAK Inhibitors
Provider: Medscape LLC
Supported by: Supported by an independent educational grant from GSK
Continuing education: For Pharmacists
Medscape designates this continuing education activity for 1.50 contact hour(s) (0.100 CEUs) (Universal Activity Number: JA0007105-0000-25-007-L01-P).
Contact hours: 1.5Program Description
In this 90-minute symposium, a panel of 3 expert managed care pharmacists will discuss evidence- and value-based strategies for optimal integration of Janus kinase (JAK) inhibitors into the treatment plan for patients with myelofibrosis (MF). The faculty will begin with an overview of the MF disease burden, prognostic risk scoring systems, and current treatment landscape, with a focus on topline clinical trial safety and efficacy data for the 4 JAK inhibitors now approved for use in higher-risk MF and MF-associated anemia. After detailed guidance on the role of pharmacists in dose optimization, mitigation and management of treatment-related adverse events (TRAEs), and patient education and counseling, the discussion will turn to economic and logistical considerations for managed care pharmacists seeking to optimize access to the full range of JAK inhibitors across the treatment continuum. The program will conclude with a roundtable discussion about overcoming barriers to successful integration of JAK inhibitors in managed care settings, closing with an interactive audience Q&A session.
Learning Objectives
Upon completion of this activity, participants will:
- Have increased knowledge regarding the
- Managed care pharmacy considerations that impact use of JAK inhibitors in management of MF
Characteristics of JAK inhibitors that drive decision making
- Have greater competence related to
- Implementing pharmacy benefit design to improve access to JAK inhibitors in management of MF
Demonstrate greater confidence in their ability to
- Optimize use of JAK inhibitors as part the MF treatment pan managed care settings
Program Manager
Nora Pettit
Medscape LLC
npettit@medscapelive.com - Tuesday, April 1, 2025 | 11:30 am - 1:30 pm
-
Location: 370 ABC
Hit the Ground Running in Crohn’s Disease: A Managed Care Guide to Advanced Biologic Therapies and Early Interventions to Improve Long-term Outcomes
Provider: ProCE, LLC
Continuing education: The target audience for this activity is population health decision-makers involved in the care of patients with CD, comprising managed care pharmacists, payers, pharmacy benefit managers, and key managed care pharmacy stakeholders, pharmacy directors, chief pharmacy officers, and other managed care professionals, as well as members of integrated delivery systems, such as specialty pharmacists.
Contact hours: 1.5Program Description
As medical science advances have generated new biologic therapies for the treatment of Crohn’s disease (CD), managed care pharmacists and other healthcare professionals who serve as population health decision-makers must stay abreast of the clinical evidence regarding the utility of new therapies in achieving the guideline-recommended treatment targets that improve long-term disease remission and ultimately help reduce healthcare utilization and costs. Evidence demonstrates that individuals with CD who reach the most stringent treatment goals of deep mucosal healing have lower rates of clinical relapse, hospitalization, surgery, and cancer. Fortunately, new and emerging biologic therapies such as selective interleukin-23 (IL-23) inhibitors are helping patients achieve rapid symptom improvement and durable disease remission. Yet, delays in treatment initiation are common and most patients do not receive early treatment with advanced therapies as recommended by expert consensus. With the significant impact of CD on both patients and the healthcare system, managed care professionals are tasked with leveraging a comprehensive understanding of disease burden andunmet needs, the latest clinical data on current and emerging therapies, and strategies for optimizing patient care.to achieve the best possible clinical outcomes.
Join us for this interactive and engaging ACPE-certified education to reflect and connect with experts on advances in biologic therapies for moderate to severe CD.
Learning Objectives
- Analyze the safety and efficacy data informing the use of selective IL-23 inhibitors in moderate to severe CD
- Assess the contribution of suboptimal therapy to healthcare utilization and costs for patients with moderate to severe CD
- Identify managed care considerations that incorporate evidence-based data on novel biologic therapies into formulary decisions and pathway development to prevent delays in therapy and improve clinical outcomes in the management of moderate to severe CD
Program Manager
Kerry Rosa
ProCE
krosa@cealliance.comRegistration Link Coming Soon
- Wednesday, April 2, 2025 | 11:30 am - 1:30 pm
-
Location: 330
Precision Meets Value: Elevating Outcomes in Relapsed/Refractory Multiple Myeloma With CAR T-Cell and Bispecific Antibody Therapies
Provider: PRIME Education, LLC
Supported by: Janssen Scientific Affairs, LLC, Legend Biotech, BMS (Pending)
Continuing education: ACPE credit for managed care pharmacists, medical and pharmacy directors, and medication therapy management (MTM) nursing directors working in managed care organizations, pharmacy benefit organizations, and specialty pharmacies
Contact hours: 1.5Program Description
The 1.5-hour live symposium and live stream will be led by a panel of one nationally renowned expert in MM, a managed care pharmacist and moderated by a clinical pharmacist to facilitate panel discussions, conduct polling, and triage questions from the audience.
The symposium’s agenda will feature real-world insights from a new managed care pharmacist survey and expert discussion on the latest evidence for bispecific antibody and CAR T-cell therapies in R/R MM, with a focus on overcoming managed care challenges and improving patient outcomes. To maximize audience engagement, the presentation will integrate real-time polling and case-based discussions supplemented by pre-submitted attendee questions and a dedicated Q&A session.
Agenda
I. Shifting the Paradigm: The Role of CAR T-Cell and Bispecific Antibody Therapies in R/R MM
a. Key updates from clinical trials and their implications for earlier treatment with CAR T-cell therapy in R/R MM
b. Optimizing patient outcomes in R/R MM: Case-based discussions
II. Real-World Insights: Survey of Managed Care Pharmacists on the Challenges and Opportunities With CAR T-Cell Therapies and Bispecific T-Cell Engagers
III. Financial Toxicity and Healthcare Resource Management: Strategies for Managed Care Pharmacists
a. Cost considerations for bispecific and CAR T-cell therapies
b. Innovative reimbursement models, such as outcome-based pricing
c. Best practices for financial navigation, outpatient management of CRS, and remote patient monitoring
d. The role of managed care pharmacists in advocating for expanded networks of certified CAR T-cell centers
IV. Q&A Session
Learning Objectives
- Analyze the latest efficacy and safety data on chimeric antigen receptor (CAR) T-cell and bispecific antibody therapies to inform formulary decisions for relapsed/refractory multiple myeloma (R/R MM)
- Apply evidence-based strategies to optimize patient selection criteria for CAR T-cell therapies and bispecific antibodies in R/R MM management, based on patient- and disease-specific factors
- Assess the impact of early identification and management of adverse events (AEs) in patients receiving CAR T-cell therapies and bispecific antibodies to enhance safety and reduce costs
- Evaluate the cost-effectiveness and financial implications of utilizing CAR T-cell therapies and bispecific antibodies in managed care settings for R/R MM treatment
- Employ strategies to mitigate financial toxicity for R/R MM patients undergoing treatment with CAR T-cell therapies and bispecific antibodies
Program Manager
Stephanie Yang
PRIME Education
s.yang@primeinc.org - Wednesday, April 2, 2025 | 11:30 am - 1:30 pm
-
Location: 370 DEF
11:30 AM-12:00 PM CDT: Registration & Lunch
12:00-1:00 PM CDT / In-Person & Virtual Symposium
Taking a Step Forward in HCM Precision Medicine: Aligning Clinical and Managed Care Approaches With New Guidelines, Long-Term Evidence, and Real-World Experience
Provider: This CME/MOC/CPE/AAPA/IPCE activity is provided by PVI, PeerView Institute for Medical Education.
Supported by: This activity is supported through an educational grant from Bristol Myers Squibb.
Continuing education: This activity has been designed to meet the educational needs of managed care, specialty, and health system pharmacists, medical directors, cardiologists, and other clinicians involved in the management of patients with HCM.
Contact hours: 1.0 CME/MOC/CPE/AAPA/IPCEProgram Description
Hypertrophic cardiomyopathy (HCM) is a cardiac condition affecting up to 1 in 200 individuals. For those who advance to severe symptomatic obstructive HCM (oHCM), surgical and pharmacological treatments are recommended to manage symptoms and reduce risks. However, most conventional treatments address symptoms only and do not directly target the underlying pathophysiology. In contrast, cardiac myosin inhibitors (CMIs) target the underlying pathophysiology of oHCM, alleviate symptoms, and improve functional outcomes. One CMI is currently approved for oHCM, with other agents and indications on the horizon. To realize the full potential of CMIs, this class must be integrated into treatment protocols—a challenge under many current pharmacy coverage policies. How should managed care professionals and healthcare providers respond?
This PeerView Clinical Consults satellite symposium during the 2025 Academy of Managed Care Pharmacy (AMCP) Annual Meeting will answer that question and more. This activity integrates key research insights with their practical application through patient scenarios. By the end of the symposium, learners will better grasp the challenges of the HCM treatment journey, as well as the long-term and real-world evidence critical to aligning therapeutic decision-making with managed care strategies. Learners will then be able to take this knowledge and understand how to integrate it into updated managed care frameworks and team-based care. Register now and step forward the future of precision medicine in HCM!
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the clinical and financial burdens associated with HCM that contribute to suboptimal health and economic/resource utilization outcomes
- Explain the latest recommendations and evidence critical to aligning managed care strategies with therapeutic decision-making in oHCM
- Incorporate clinical features, pharmacoeconomic considerations, health equity, and patient-related factors into updated managed care frameworks and interprofessional strategies for the precision treatment of oHCM
Program Manager
Amanda Loeber
PVI, PeerView Institute for Medical Education
amanda.loeber@peerview.com